James R. Gavin III, MD, PhD - The Contemporary Use of GLP-1 RAs to Individualize Therapy in T2DM: Candid Conversations on Glycemic and Nonglycemic Effects

Go online to PeerView.com/BDQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The availability of poly (ADP-ribose) polymerase (PARP) inhibitors has increased opportunities for healthcare professionals to improve outcomes for patients with advanced ovarian cancer through personalized medicine. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, PARP inhibitors are indicated by the FDA for use in patients with BRCA-deficient tumors, homologous recombination deficient (HRD) tumors, and biomarker wild-type tumors and are being investigated in combination with other systemic agents, including targeted therapies, chemotherapy, and immunotherapy, in an effort to overcome PARP resistance and exploit additive efficacy. Join PeerView and the National Ovarian Cancer Coalition for an educational activity that will combine a review of key data on PARP inhibitors with practical expert guidance on integrating these agents into clinical practice. Using PeerView’s unique “Candid Conversations & Clinical Consults” format, this activity will provide participants with multiple perspectives, including those from clinicians in academic and community settings, patients, and advocates; opportunities to reflect on how treatment advances will affect patient care; and a venue for having oncology experts answer their questions on using PARP inhibitors in a variety of settings. With case patients drawn from practice serving as the framework for activity, the expert faculty panel will delve into critical concepts, including genetic testing guidelines, clinical trial enrollment, and recognizing and managing adverse events associated with PARP inhibitors, and engage in interactive discussions that will bring clinical decision points to life. Upon completion of this accredited CE activity, participants should be better able to: Assess the rationale for and latest clinical evidence on available and emerging PARP inhibitor agents and combinations for patients with primary and recurrent advanced ovarian cancer, Apply current clinical practice recommendations for germline and tumor genetic testing in patients with advanced ovarian cancer, Integrate PARP inhibitors into personalized management plans, including in the context of clinical trials, for eligible patients with primary and recurrent advanced ovarian cancer, Employ appropriate strategies to manage the unique safety issues related to the use of PARP inhibitors, including with long-term use associated with maintenance settings, in patients with advanced ovarian cancer.